Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit

Pfizer has intensified its legal challenge against Novo Nordisk, filing a second lawsuit alleging Novo's $9 billion bid for biotech Metsera is a strategic tactic to delay Metsera's entry into the lucrative obesity drug market and suppress competition. Pfizer claims Novo's offer includes a 30-month 'outside date' and restrictive covenants designed to impede Metsera's drug development and protect Novo's dominant market share, contrasting with Pfizer's own prior $7.3 billion deal which had a shorter timeline. Novo and Metsera, which is developing a next-generation obesity drug, have rejected Pfizer's accusations, setting the stage for a judicial review and underscoring the fierce competition in the rapidly expanding $150 billion obesity market.

Analysis

Pfizer has intensified its legal challenge against Novo Nordisk, alleging Novo's $9 billion bid for biotech Metsera is an anti-competitive maneuver to delay market entry for Metsera's next-generation obesity drug. Pfizer claims Novo's offer includes a 30-month "outside date" and restrictive covenants, contrasting with Pfizer's earlier $7.3 billion agreement which had a 9-month timeline and expedited antitrust review. This dispute highlights the fierce competition for control of Metsera's promising monthly-injection therapy in the rapidly expanding obesity market.

The legal battle introduces significant uncertainty into the acquisition process, impacting Metsera's valuation and market sentiment. Metsera shares fell 3.7% on Monday to $60.73, while Pfizer's stock remained flat and Novo Nordisk saw a less than 1% decline. Pfizer views Metsera as crucial for entering the $150 billion obesity market, making the stakes high for all involved parties.

A Delaware court is set to review the complaints on Tuesday, a critical event that will shape the immediate future of the deal. The allegations of strategic delay and efforts to suppress competition suggest a protracted legal process, potentially hindering Metsera's drug development and altering the competitive dynamics for GLP-1 agonists.

Key Decisions for Investors

• Investors should closely monitor the Delaware court's ruling on Tuesday, as it will significantly influence the viability and timeline of the Metsera acquisition for both Pfizer and Novo Nordisk
• Assess the potential for prolonged litigation to impact Metsera's drug development schedule and its competitive entry into the lucrative obesity market
• Evaluate the strategic implications for Pfizer's obesity market entry and Novo Nordisk's competitive position, especially regarding the potential for delayed market access for Metsera's novel therapy